EcoR1 Capital, LLC 13D and 13G filings for iTeos Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-05-16 7:22 pm Purchase |
2025-05-15 | 13D | iTeos Therapeutics, Inc. ITOS |
EcoR1 Capital, LLC | 10,688,978 27.900% |
4,958,978 (+86.54%) |
Filing |
| 2025-05-13 7:10 pm Purchase |
2025-05-13 | 13G | iTeos Therapeutics, Inc. ITOS |
EcoR1 Capital, LLC | 5,730,000 14.900% |
3,073,360 (+115.69%) |
Filing |
| 2025-05-08 7:43 pm Purchase |
2025-05-01 | 13G | iTeos Therapeutics, Inc. ITOS |
EcoR1 Capital, LLC | 2,656,640 6.900% |
1,048,024 (+65.15%) |
Filing |
| 2024-11-14 6:04 pm Sale |
2024-09-30 | 13G | iTeos Therapeutics, Inc. ITOS |
EcoR1 Capital, LLC | 1,608,616 4.400% |
-336,056 (-17.28%) |
Filing |
| 2024-02-16 12:54 pm Purchase |
2024-02-05 | 13G | iTeos Therapeutics, Inc. ITOS |
EcoR1 Capital, LLC | 1,944,672 5.400% |
1,944,672 (New Position) |
Filing |